Valuation: Tyra Biosciences, Inc.

Market Cap 1.91B 1.67B 1.54B 1.42B 2.68B 184B 2.74B 18.42B 7.24B 90.12B 7.18B 7.02B 310B P/E 2026 *
-12.4x
P/E 2027 * -11.3x
Enterprise Value 1.5B 1.31B 1.21B 1.11B 2.1B 144B 2.15B 14.46B 5.69B 70.74B 5.63B 5.51B 244B EV / Sales 2026 *
-
EV / Sales 2027 * 524x
Free-Float
97.14%
Yield 2026 *
-
Yield 2027 * -
1 day+1.65%
1 week-1.89%
Current month+0.59%
1 month+13.45%
3 months-9.65%
6 months+11.68%
Current year+22.21%
1 week 30.08
Extreme 30.08
33.72
1 month 28.06
Extreme 28.06
33.72
Current year 24.66
Extreme 24.66
40.65
1 year 9.96
Extreme 9.96
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 2018-10-31
Chief Executive Officer 46 2018-10-31
Director of Finance/CFO 69 2022-12-31
Director TitleAgeSince
Chairman 58 2019-02-28
Director/Board Member 46 2018-08-01
Director/Board Member 40 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
5/28/26 Free

Director

13,160 0.0221%
5/28/26 Free

Director

13,160 0.0221%
5/28/26 Free

Director

13,160 0.0221%
Change 5-day change 1-year change 3-year change Capi.($)
+1.65%-1.89%+209.24%+117.09% 1.91B
-7.17%-4.39%+42.72%+73.32% 52.1B
+0.24%-1.54%+52.85%+71.85% 53.83B
+0.80%-6.31%+5.62%+417.78% 23.48B
-0.09%-0.01%-16.85%-15.41% 23.13B
-5.95%-2.58%+29.53%-9.47% 19.36B
-1.14%+0.03%+31.67%-30.65% 17.56B
-5.16%-7.00%+168.44%+314.96% 15.2B
-6.91%-5.83%+25.17%+644.30% 14.83B
+0.43%-1.03%+25.75%+189.74% 14.06B
Average -2.33%-2.55%+57.41%+177.35% 23.55B
Weighted average by Cap. -2.76%-2.35%+40.92%+142.92%

Financials

2026 *2027 *
Net sales - 3.1M 2.71M 2.5M 2.3M 4.34M 299M 4.44M 29.88M 11.75M 146M 11.64M 11.39M 503M
Net income -166M -145M -133M -123M -232M -15.94B -237M -1.6B -627M -7.81B -622M -608M -26.87B -196M -171M -158M -146M -274M -18.86B -280M -1.89B -742M -9.23B -735M -719M -31.79B
Net Debt -411M -359M -331M -305M -576M -39.57B -588M -3.96B -1.56B -19.38B -1.54B -1.51B -66.71B -287M -251M -231M -213M -402M -27.63B -411M -2.76B -1.09B -13.53B -1.08B -1.05B -46.58B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
26-07-17 US$32.13 +1.65% 621,567
26-07-16 US$31.61 -2.38% 473,666
26-07-15 US$32.38 -1.52% 388,743
26-07-14 US$32.88 +0.64% 580,367
26-07-13 US$32.67 -0.24% 642,107
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
32.13USD
Average target price
51.97USD
Spread / Average Target
+61.74%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock